SC-002 in Small Cell Lung Cancer and Large Cell Neuroendocrine Carcinoma
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT02500914 |
Recruitment Status :
Terminated
(Strategic Considerations)
First Posted : July 17, 2015
Last Update Posted : October 5, 2018
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
This is a Phase 1a/1b study of SC-002 in patients with relapsed small cell lung cancer (SCLC) or large cell neuroendocrine carcinoma (LCNEC). SC-002 is an antibody-drug conjugate (ADC) comprised of a monoclonal antibody linked to a potent chemotherapy.
The purpose of this study is to assess the safety and tolerability of SC-002 at different dose levels, to determine the highest dose of SC-002 that can be given to patients with SCLC or LCNEC, to evaluate the side effects of SC-002, and to assess the anti-cancer activity of SC-002.
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Small Cell Lung Cancer | Drug: SC-002 | Phase 1 |
Part 1A is a dose escalation study in patients with small cell lung cancer or large cell neuroendocrine carcinoma with cytologically confirmed, limited or extensive SCLC or LCNEC that have relapsed or refractory limited or extensive disease following no more than 2 prior chemotherapy regimens.
Part 1B is an expansion study where patients will be enrolled and treated in order to further characterize safety and preliminary efficacy in patients with SCLC or LCNEC and further characterize PK, immunogenicity and target expression and possible relationship to clinical outcome.
Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 35 participants |
Allocation: | N/A |
Intervention Model: | Single Group Assignment |
Masking: | None (Open Label) |
Primary Purpose: | Treatment |
Official Title: | A Phase 1a/1b Dose Escalation and Expansion Study of Single-agent SC-002 in Subjects With Relapsed or Refractory Small Cell Lung Cancer and Large Cell Neuroendocrine Carcinoma |
Study Start Date : | June 2015 |
Actual Primary Completion Date : | August 23, 2018 |
Actual Study Completion Date : | August 23, 2018 |

Arm | Intervention/treatment |
---|---|
Experimental: SC-002
Part 1A (Dose Escalation) - IV infusion; safety data will be reviewed prior to dose escalation decision. Dose escalation will complete when recommended dose (RD) is determined. RD will be the maximum tolerated dose (MTD) or lower dose that provides adequate PK exposure, immunogenicity, and preliminary evidence of antitumor activity with tolerability. Part 1B (Dose Expansion) - IV infusion; once MTD and/or RD has been determined in Part 1A, an expansion cohort of approximately 60 patients with SCLC or LCNEC will be enrolled to further characterize the safety profile and clinical activity of the RD. Patients may continue treatment until disease progression, unacceptable toxicity, or withdrawal of consent. |
Drug: SC-002
SC-002 will be administered by IV infusion over approximately 30 minutes every 3 weeks |
- Maximum tolerated dose [ Time Frame: 6 months ]
- Number of subjects with adverse events as a measure of safety and tolerability [ Time Frame: 6 months ]
- Pharmacokinetics of SC-002 [ Time Frame: Cycle 1 and 4: days 1, 2, 4, 8, 15; Cycles 2, 3, and 5: day 1 only ]Standard PK variables to be assessed include AUC, Tmax, Cmax, Ctrough, T1/2, CL, Vss
- RECIST v1.1 assessed objective response rate [ Time Frame: 6 months ]

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Histologically or cytologically confirmed SCLC (either limited or extensive disease) or LCNEC, that has relapsed from the most current treatment or was refractory to treatment
- Evidence of progressive disease during or following no more than 2 prior chemotherapy regimens
- Measurable disease as defined by RECIST
- ECOG performance status of 0 or 1
- Adequate hematological and organ function as confirmed by laboratory values
- Treatment with anticancer/investigational drugs, therapy ≤ 4 weeks prior to first dose of SC-002
Exclusion Criteria:
- Active central nervous system metastases
- Uncontrolled cardiac disease
- Positive serology for hepatitis B or hepatitis C or known HIV infection
- Presence of any condition that may increase the risks associated with study participation and interfere with the interpretation of study results

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02500914
United States, Michigan | |
Ann Arbor, Michigan, United States, 48109 | |
United States, Missouri | |
Saint Louis, Missouri, United States, 63110 | |
United States, New York | |
New York, New York, United States, 10065 | |
United States, Tennessee | |
Nashville, Tennessee, United States, 37203 |
Study Director: | Julia Lawrence, D.O. | Novella Clinical |
Responsible Party: | Stemcentrx |
ClinicalTrials.gov Identifier: | NCT02500914 |
Other Study ID Numbers: |
SCRX002-001 |
First Posted: | July 17, 2015 Key Record Dates |
Last Update Posted: | October 5, 2018 |
Last Verified: | October 2018 |
small cell lung cancer |
Lung Neoplasms Small Cell Lung Carcinoma Carcinoma, Neuroendocrine Carcinoma Neoplasms, Glandular and Epithelial Neoplasms by Histologic Type Neoplasms Respiratory Tract Neoplasms Thoracic Neoplasms Neoplasms by Site |
Lung Diseases Respiratory Tract Diseases Carcinoma, Bronchogenic Bronchial Neoplasms Neuroendocrine Tumors Neuroectodermal Tumors Neoplasms, Germ Cell and Embryonal Adenocarcinoma Neoplasms, Nerve Tissue |